Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT

J Am Coll Cardiol. 2022 Jan 18;79(2):220-222. doi: 10.1016/j.jacc.2021.11.005.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases / prevention & control
  • Eicosapentaenoic Acid / analogs & derivatives*
  • Eicosapentaenoic Acid / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypertriglyceridemia / drug therapy*
  • Lipid Regulating Agents / therapeutic use*
  • Randomized Controlled Trials as Topic

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipid Regulating Agents
  • eicosapentaenoic acid ethyl ester
  • Eicosapentaenoic Acid

Associated data

  • ClinicalTrials.gov/NCT01492361